IndraLab
Statements
reach
"A great achievement was reached when a potent diarylsulfonylurea compound MCC950 (also termed as CRID3, CP-456773), endowed with NLRP3 selectivity, showed therapeutic improvement in several preclinical models such as experimental autoimmune encephalomyelitis, such as AD and PD [229-232], nevertheless it failed in clinical trials because of off-target toxicity.In the search for new inhibitors Stavudine (d4T), acting as an inhibitor of nucleoside reverse transcriptase, has been published recently to downregulate NLRP3 activation in AD [233]."